The cost for treating diabetes is expected to come down with a Delhi High Court having dismissed an appeal by AstraZeneca, which had sought the restraining of the generic versions of a blockbuster drug. The global pharma firm was also suing a host of domestic companies for the infringement of patents covering the drug. The High Court order paves the way for more affordable versions by domestic companies in India of the blockbuster anti-diabetes drug Dapagliflozin in the market. You can read more at: http://timesofindia.indiatimes.com/articleshow/84623779.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Menu